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outcomes and greater indirect costs. The distribution of BMI is similar to the 5 E.U. 
Finding suggest the need for additional weight-loss options.
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Objectives: MCD, an ultra-orphan lymphoproliferative disorder with heteroge-
neous symptomology, including fatigue, malaise, sweats, and nodal/extranodal 
masses, is driven by dysregulated interleukin-6 signaling. Siltuximab, an anti-
interleukin-6 antibody, is approved in the US and EU for treatment of human immu-
nodeficiency virus (HIV) - and human herpes virus-8 (HHV-8) -negative adult MCD 
patients. This study aimed to fill an unmet need for a validated PRO tool to quantify 
MCD symptoms and responses to therapy. MethOds: Using FDA guidance, an MCD 
symptom scale (MCD-SS) was developed by collecting and evaluating symptoms 
in 12 patients from 2 US centers, with further validation using additional patients 
from 1 US center. Item performance, scale structure and scoring, reliability, validity, 
responsiveness, and clinically meaningful change were evaluated in a randomized, 
placebo-controlled, double-blind study of siltuximab (N= 79) in HIV-, HHV-8-negative 
MCD patients (Wong Blood 2013:122 (21)). Results: Patient-reported MCD symp-
toms were: cough, dizziness, drowsiness, dry mouth, fever, headaches, hot flashes, 
itching, skin lesions, loss of appetite, nausea, numbness/tingling, pain, rash, short-
ness of breath, sweating, swollen lymph nodes, swelling/edema, tiredness/fatigue, 
vomiting, weakness, weight gain, and weight loss. Following exploratory factor 
analysis, 3 domains were created: fatigue, rash/itching, and sweats (total score also 
calculated). The final MCD-SS comprised 16 questions with 6 response options: “did 
not experience,” “very mild,” “mild,” “moderate,” “severe,” and “very severe” (score, 
0-5). Subjects reported a mean (SD) and median (range) of 9.2 (3.76) and 9.5 (1-16) 
symptoms, respectively. Test-retest reliability was acceptable (r> 0.70) for fatigue, 
sweats, and the total score but lower for rash/itching (r= 0.65). Internal consistency 
exceeded 0.70 for all. Lower ECOG scores were associated with lower MCD-SS scores. 
MCD-SS total scores were moderately correlated (r= 0.48) with baseline clinician-
reported signs and symptoms. cOnclusiOns: This is the first known attempt to 
develop a PRO instrument for MCD. These data support further use of the MCD-SS 
in the target population.
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Objectives: Systemic sclerosis (SSc) is a rare, multisystem chronic disease char-
acterised by fibrotic changes affecting all or some bodily organs. SSc is associated 
with high morbidity and a significant effect on patients’ health-related quality 
of life. Qualitative insights can provide rich context to the patients’ experience 
of a disease. Conceptual models based on qualitative data are a valuable way to 
“explain, with graphically or narrative form, the main things to be studied - the key 
factors, concepts and variables – and the presumed relationships between them”. 
Despite the existence of SSc-specific measures, no conceptual model of SSc exists. 
This research aimed to develop a qualitatively-derived, patient-centred, conceptual 
model of SSc. MethOds: To identify patient-reported SSc symptoms and impacts, 
we reviewed qualitative literature (published since 2000 to limit the search) in 
which experiences of living/coping with SSc are described. We also reviewed social 
media blogs/forums to identify additional concepts and provide supporting quotes. 
Concepts were identified by independent researchers who collaboratively developed 
the model. Results: Twelve qualitative studies and 150 social media posts were 
reviewed. The review identified 56 symptom concepts, which were categorised into 
13 domains (peripheral, cognitive, pain, neurological, cardiorespiratory, ophthalmo-
logical, gastrointestinal, fatigue, nasopharyngeal, weight, oesophageal, dizziness, 
nausea) and 48 impact concepts, which were categorised into 8 domains (daily living, 
diet, social, clothing, work, physical and psychological functioning). Of note, nausea 
and dizziness were identified only through the social media review. cOnclusiOns: 
A conceptual model for SSc was developed based on qualitative insights. The model 
depicts the diverse range of symptoms and impacts experienced by patients. By 
incorporating a social media review, relevant symptoms, which would not have 
otherwise been identified, were found and included in the model. This research is 
an important first step in identifying the most relevant and conceptually compre-
hensive clinical outcomes assessments for clinical research/practice.
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Objectives: The objectives of this study were to investigate the prevalence of 
Neuropathic Pain (NP) and newly occurred (de novo) NP postoperatively. This study 
also aimed to identify the disease burden (pain severity and quality of life (QoL)) 
of NP. MethOds: This study was a nationwide, multi-centered, prospective, and 
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Objectives: Adherence to iron chelation therapy (ICT) is essential for patients with 
transfusion-dependent anemia (TDA) (e. g., sickle cell disease [SCD] and thalas-
semia) to increase survival and minimize disease-related sequellae. Adherence has 
been noted as especially problematic for children and adolescents. In order to meas-
ure compliance and treatment satisfaction in young children, the Satisfaction with 
Iron Chelation Therapy (SICT) instrument (initially developed for use by adults and 
adolescents) was modified to be an observer-reported outcome (ObsRO) measure to 
be administered electronically to caregivers. In addition, three other ObsROs were 
developed measuring compliance, palatability, and gastrointestinal (GI) symptoms 
related to treatment benefit of a new ICT formulation. MethOds: Subjects included 
10 caregivers of children with TDA. Informed consent was obtained. Two sets of 
face-to-face cognitive interviews were conducted iteratively with modification to 
items and further debriefing of modifications. Interviews began with an open-ended 
question to elicit caregivers’ and their reports of their child’s experiences with 
ICT. Interviews were audio recorded and transcribed. Data were analyzed using 
ATLAS. ti software. Results: Three interviewers conducted 10 caregiver inter-
views in 6 US cities. Caregivers were 90% female aged 35-65 (mean= 48). Children 
of caregivers included those with SCD (80%) and thalassemia (20%) and were 60% 
female, aged 2-17 (mean= 9). Responses to the open-ended question confirmed 
several concepts in the modified SICT and the need for new items. The result-
ant questionnaires included the modified SICT (17 items), Compliance (2 items), 
Palatability (4 items), and GI Symptom Diary (6 items). Changes were made to each 
to ensure comprehension, relevance, lack of redundancy, and appropriate response 
options. cOnclusiOns: Evidence supports the content validity of the modified 
SICT, Compliance, Palatability, and GI Symptom Diary questionnaires. Use in clinical 
research awaits tests of validity, reliability, and responsiveness.
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Objectives: Pulmonary exacerbations (PEs) in patients with cystic fibrosis (CF) 
have been reported to impact health-related quality of life. This analysis exam-
ined the impact of PEs on EQ-5D measures in patients with CF using trial-based 
data. MethOds: In a 48-week randomized, placebo-controlled study of ivacaftor 
in patients ≥ 12 years with CF and a G551D-CFTRmutation, the EQ-5D questionnaire, 
including visual analog scale (EQ VAS), was administered at baseline, 15 days, 8 
weeks, and every 8 weeks thereafter. UK preference weights were employed to 
derive the EQ-5D index. PE was defined as a change in antibiotic therapy for ≥ 4 of 
12 signs or predefined symptoms. EQ-5D measures collected in the 8-week pre- and 
post- exacerbation periods were examined after pooling observations across study 
treatments and visits. Results: A total of 146 PEs were experienced by 72 (44.7% of 
total 161) patients, including 52 (35.6%) PEs that required hospitalization. Mean (±SD) 
duration was 30.0±22.2 days for PEs requiring hospitalization (n= 48) and 20.6±11.6 
days for those not requiring hospitalization (n= 89) (9 PEs had missing end dates). 
For PEs requiring hospitalization, mean (±SD) EQ-5D index/VAS scores within 1-8 
weeks before PE start were 0.91 (±0.13)/75.5 (±14.2), respectively. The lowest aver-
age EQ-5D index/VAS scores were reached within 1 week of PE start; mean scores 
within 1 week were 0.76±0.33 (p= 0.044 vs. 1-8 weeks prior to PE) /63.7±24.1 (p= 0.039). 
Corresponding values for PEs not requiring hospitalization were 0.89±0.16/73.4±16.1 
within 1-8 weeks before PE start, and 0.90±0.13 (p= 0.777) /68.4±17.4 (p= 0.124) within 
1 week of PE start. cOnclusiOns: In a clinical study of patients with CF (≥ 12 years 
of age and a G551D-CFTR mutation), the PEs were associated with lower EQ-5D and 
VAS scores, primarily among those requiring hospitalization. Reducing PEs requir-
ing hospitalization is likely to improve health-related quality of life among these 
patients.
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Objectives: This study investigated the effect of BMI on quality of life, pro-
ductivity, activity impairment, health care resource-utilisation, and associated 
costs. MethOds: Results were from the 2011-2012 Brazil National Health and 
Wellness Survey (N= 24,000), a nationally representative, online survey of respond-
ents aged≥ 18 years. Analysis focused on normal weight (BMI≥ 18.5 & < 25 kg/m2), 
overweight (BMI≥ 25 & < 30 kg/m2), obese class (OC) I (BMI≥ 30 & < 35 kg/m2), OC II 
(BMI≥ 35 & < 40 kg/m2), and OC III (BMI≥ 40 kg/m2) respondents. Outcomes included 
quality of life (SF-36v2), health utilities (SF-6D), productivity loss (Work Productivity 
and Activity Impairment questionnaire) and resource utilisation (type/number of 
visits) in the past six months. Direct and indirect costs were estimated from public 
sources. Generalised linear models predicted outcomes as a function of BMI cat-
egory, adjusting for covariates (e. g., age, gender, comorbidities). Results: Among 
22,871 respondents, 46.4% were normal weight, 34.9% were overweight, 12.9% were 
OC I, 3.7% were OC II, and 2.0% were OC III. Adjusting for covariates, mental, physi-
cal component summary (normal weight: 51.8; overweight: 51.4; OC I: 50.3; OC II: 
48.5; OC III: 46.0), and health utilities (normal weight: 0.73; overweight: 0.72; OC I: 
0.71; OC II: 0.70; OC III: 0.67) decreased as BMI increased (OCs vs. normal, p< 0.05). 
Amongst the employed (66.1%), impairment while working (normal weight: 15.5%; 
overweight: 15.6%; OC I: 16.9%; OC II: 18.2%; OC III: 22.4%, OCs vs. normal, p< 0.05) 
increased as BMI increased. Normal weight (vs. OCs, p≤ 0.05) had lower activity 
impairment, fewer provider visits, and lower indirect costs (normal weight: R$333; 
overweight: R$338; OC I: R$385; OC II: R$395; OC III: R$458). cOnclusiOns: Over 
50% of Brazilians are overweight or obese. Increase in BMI is associated with poorer 
